Purpose: This randomized phase II study was initially designed to test the activity of two dose schedules of lapatinib (GW572016H), an oral, reversible, dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human EGFR-2 (HER2/neu; HER2), in chemotherapy-naive patients with non-small cell lung cancer (NSCLC); it was later amended to target patients with bronchioloalveolar carcinoma or no smoking history.
Lung cancer is the leading cause of cancer-related deaths worldwide, with an estimated incidence of 1.35 million cases resulting in 1.2 million deaths annually (1) . With advances in the treatment of newly diagnosed advanced non-small cell lung cancer (NSCLC), survival in patients able to receive chemotherapy has improved modestly over the past 2 decades (2). Platinum-based chemotherapy offers an initial response rate of 15% to 30%, with a median survival of 8 to 14 months. Approximately 35% to 50% of patients with good performance status will survive 1 year, although only 15% to 20% of patients survive 2 years from initial diagnosis (3) (4) (5) . Targeted agents such as bevacizumab may add efficacy in selected patients at the cost of additional toxicity (6) . Current strategies for drug design are focused on molecular mechanisms of tumorigenesis, such as the activation of protein kinases by somatic mutation or amplification.
The finding that members of the ErbB gene family are often amplified or mutated in NSCLC has led to this family as a target of investigation (7) .
The human ErbB receptor family consists of four transmembrane glycoproteins involved in transmission of signals controlling cell growth and differentiation. Two members of this family, epidermal growth factor receptor (EGFR) and human EGFR-2 (HER2), are transmembrane tyrosine kinase receptors expressed on normal epithelial cells but overexpressed on some cancer cells (8, 9) . In NSCLC, overexpression of EGFR ranges from 43% to 89% and that of HER2 from 16% to 32% (10) . Some studies have shown no correlation between expression of these receptors and disease severity or clinical outcome (11) , whereas others have shown an association between EGFR overexpression and poor prognosis in NSCLC, or between elevated levels of EGFR phosphorylation and time to disease progression (12, 13) .
EGFR and HER2 have been the targets of considerable research to develop therapies that will interfere with their oncogenic potential. Activation of the ErbB family of receptors requires homodimerization or heterodimerization. HER2 is the preferred dimerization partner for all other members of the family; thus, EGFR preferentially forms heterodimers with HER2 (14) . Available small-molecule EGFR tyrosine kinase inhibitors inhibit EGFR homodimers but may be less effective at inhibiting heterodimers of EGFR and HER2.
Lapatinib is a novel, small-molecule, tyrosine kinase inhibitor of both EGFR and HER2. As EGFR can signal via both homodimers and heterodimers with HER2, dual inhibition of both receptors should be advantageous. Clinical studies are required to determine whether the theoretical benefit of dual ErbB tyrosine kinase inhibition will improve patient outcomes compared with inhibitors of either EGFR or HER2 alone.
The current study was initially developed to evaluate lapatinib for first-line treatment of unselected patients with advanced NSCLC. The three main histologic subtypes of NSCLC (squamous, large cell, and adenocarcinoma) have until recently been grouped together due to their similar natural history and response to cytotoxic chemotherapy. While the current trial was being conducted, preclinical and clinical evidence began to suggest greater efficacy of EGFR tyrosine kinase inhibitors in patients with advanced NSCLC who had never smoked or who had bronchioloalveolar carcinoma (BAC; ref. 15) , perhaps because of an alternate mechanism of carcinogenesis in these patients involving EGFR mutations and/or amplification. BAC is a subset of adenocarcinoma that has been increasing in incidence over recent years. "Pure" BAC, defined as having a purely lepidic spreading pattern with no evidence of stromal, vascular, or pleural invasion, represents <5% of NSCLC cases (15) . Along with its variants (adenocarcinoma with BAC features), it represents ∼20% of NSCLC (15, 16) . In a study of subjects with advanced BAC treated with gefitinib (16), median overall survival was 13 months, and there was a significant difference in overall survival between patients who had never smoked (26 months) and current/former smokers (10 months). In the same study, progression-free survival after treatment with gefitinib was 3 months in previously treated subjects and 4 months in previously untreated subjects (16) . Treatment of advanced BAC with paclitaxel (17) resulted in median progression-free survival of 5 months and median overall survival of 12 months.
BACs express higher levels of both EGFR and HER2 than do other NSCLC histologies (10, 18) . In early studies, patients with BAC were disproportionately represented among those who responded to EGFR tyrosine kinase inhibitors, with some patients showing dramatic and rapid responses (15) . However, in the largest study reported to date, only never-smoking status, adenocarcinoma histology, and EGFR expression were independent predictors of response (19) . Because BAC expresses both EGFR and HER2, with very high levels of HER2 (63%) compared with other NSCLC subtypes (18), we hypothesized that a dual kinase inhibitor of both EGFR and HER2, such as lapatinib, might be particularly effective in the treatment of patients with BAC or never smokers. Consequently, the ongoing trial was amended to target patients with locally advanced or metastatic NSCLC with (a) adenocarcinoma with BAC features or pure BAC or (b) never smokers with any histology of NSCLC. The primary objective of the amended study was to evaluate the overall tumor response rate in patients treated with oral lapatinib at either 1,500 mg once daily or 500 mg twice daily.
Materials and Methods
Patients. Eligible patients were ≥18 y of age with histologically confirmed advanced (stage IIIB or IV; ref. 20) 
Translational Relevance
The primary objective of this study was to evaluate the overall response rate to lapatinib in patients with advanced non-small cell lung cancer. During the trial, studies of tyrosine kinase inhibitors in non-small cell lung cancer reported that epidermal growth factor receptor mutations were highly predictive of response. Therefore, this study was amended to target patients with bronchioloalveolar carcinoma or never smokers because these individuals were most likely to have epidermal growth factor receptor mutations and might be more likely to respond to lapatinib therapy. Although well tolerated, oral lapatinib (1,500 mg once daily and 500 mg twice daily) failed to achieve a predetermined response rate in the target population, although there were several patients with long-duration stabilization of disease. Lapatinib as a single agent at the doses studied seems to have minimal single-agent activity, at least as measured by response rates. Although there may be a subgroup of patients who benefit, such as patients with HER2 amplification, this could not be determined by the current study.
NSCLC at primary diagnosis or relapsed after curative-intent surgery. Following amendment of the protocol (July 12, 2004) , only patients with (a) adenocarcinoma with BAC features or pure BAC (21) or (b) never smokers (<100 cigarettes in lifetime) with any histology of NSCLC were eligible. Patients in the targeted group could have had a maximum of one prior systemic therapy (chemotherapy or biological therapy) for NSCLC that ended at least 3 wk before enrollment. Patients who had received adjuvant chemotherapy that ended at least 3 mo before enrollment were also eligible. Prior surgery and radiotherapy were permitted. Other criteria for eligibility included Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, normal cardiac ejection fraction, and measurable lesion(s) as defined by Response Evaluation Criteria in Solid Tumors (RECIST; ref. 22) . Women of childbearing potential were eligible to participate if they had a negative serum pregnancy test at screening and agreed to complete abstinence or an acceptable method of birth control. Availability of archived tumor tissue for evaluation of relevant biomarkers was required for all patients; however, biomarker results were not used to determine patient eligibility.
Exclusion criteria included malabsorption syndrome, disease significantly affecting gastrointestinal function, resection of the stomach or small bowel, and ulcerative colitis; concurrent disease or condition that would have made the patient inappropriate for study participation; unresolved or unstable serious toxicity from prior therapy; any condition that would have prohibited the understanding or rendering of informed consent; uncontrolled angina, arrhythmias, or congestive heart failure; prior therapy with any EGFR and/or HER2 inhibitor; and known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to lapatinib. Patients were excluded if they had taken amiodarone within 6 mo before the first dose of study medication or other inhibitors of cytochrome P450 (CYP) isoenzyme CYP3A4 within 7 d before the first dose of study medication, or if they had taken inducers of CYP3A4 within 14 d before the first dose of study medication.
Written informed consent was obtained from each patient before the performance of any study-specific procedures. The study protocol, amendments, informed consent, and other information that required preapproval were reviewed and approved by a national, regional, or investigational center ethics committee or institutional review board.
Study design. This was a randomized, open-label, parallel-group, multicenter, phase II study. A total of 120 patients were to be randomly assigned in approximately equal proportions to one of two treatment groups (oral lapatinib, 1,500 mg once daily or 500 mg twice daily). Targeted patients were stratified by histology [adenocarcinoma with BAC features or pure BAC (referred to collectively as BAC) versus no BAC], smoking history (current/former smoker versus never-smoker), and prior chemotherapy (0 versus 1). Patients were to continue to receive lapatinib until disease progression or withdrawal from lapatinib therapy for any reason.
A two-stage design was used with a stopping rule to allow early termination of the study at the end of stage I if there were concerns about safety or if there was evidence of lack of efficacy in both treatment groups based on tumor response rate. The protocol was amended to do an interim analysis on the first 30 patients meeting the requirements of the targeted population. Due to the rapid rate of accrual, 131 patients (56 targeted and 75 nontargeted) had been enrolled by the time data from those 30 targeted patients were available.
Clinical and laboratory parameters were assessed to evaluate disease response and toxicity of oral lapatinib. Safety and activity were assessed at 4-and 8-wk intervals, respectively, and at the end of treatment. Patients who stopped lapatinib without disease progression were assessed every 8 wk until progression. Thereafter, patients were followed for survival at ∼2-mo intervals.
Study populations. Three populations were analyzed. The targeted population consisted of all randomized patients who received one or more dose of investigational product and were either never smokers or had adenocarcinoma with BAC features or pure BAC; patients enrolled before or after study amendment but meeting the targeted criteria were included in the targeted population. The targeted population was the primary population for the analysis of the efficacy end points. The nontargeted population consisted of all randomized patients who received one or more dose of investigational product but who did not satisfy the criteria for inclusion in the targeted population. These two groups were analyzed by intent to treat. The safety population consisted of all randomized patients who received one or more dose of investigational product and was based on the actual treatment received.
Treatment. Lapatinib was supplied as 250-mg tablets. For patients assigned to the once-daily regimen, the daily dose of lapatinib was 1,500 mg (six tablets) to be taken ≥1 h before or after breakfast. For patients assigned to the twice-daily regimen, each dose of lapatinib was 500 mg (two tablets), for a total of 1,000 mg daily. The first dose was to be taken ≥1 h before or after breakfast; the second dose was to be taken ∼12 h after the first dose, ≥1 h before or after dinner. The number of tablets dispensed to and taken by each patient was recorded. Dose delays up to 2 wk and dose reductions were permitted in the event of toxicity.
Criteria for evaluation. The primary end point was tumor response rate by RECIST as determined by independent review. Planned secondary efficacy measures included time to response, duration of response, time to tumor progression, median progression-free survival, and overall survival.
Safety was monitored by clinical adverse events (AE), laboratory (hematology, clinical chemistry, and urinalysis) testing, electrocardiograms, echocardiograms/multigated acquisition scans, and collection of vital signs, weight, and ECOG status.
Cardiovascular events have been reported in patients taking compounds that inhibit HER2, and interstitial pneumonitis has been noted in patients taking agents that inhibit EGFR. In this study, cardiac dysfunction was reported as a serious AE (SAE); it was defined as any signs or symptoms of deterioration in left ventricular cardiac function of grade ≥3 (National Cancer Institute Common Terminology Criteria for Adverse Events) or an asymptomatic, relative decline in left ventricular cardiac ejection fraction of ≥20% from baseline and below the institution's lower limit of normal. In addition, any signs or symptoms of pneumonitis of grade ≥3 (National Cancer Institute Common Terminology Criteria for Adverse Events) were to be reported as a SAE.
PCR and DNA sequence analysis. Sequencing of EGFR (exons 18-24, tyrosine kinase domain) and HER2 (exons 18-24, tyrosine kinase domain) genes, including intronexon boundaries, was done by PCR amplification of DNA from archived paraffin-embedded tumor tissue samples and direct sequencing of both strands. All PCR primers were designed using Primer D software (GlaxoSmithKline internal software) and ordered from Integrated DNA Technologies, Inc. PCR primers were tailed with M13 universal sequencing primer sequences. Primers to amplify exons were designed within 100 bases of flanking intronic sequences. All PCRs were carried out in a 25-μL volume containing 20 ng of genomic DNA using HotStarTaq DNA polymerase (Qiagen, Inc.). DNA was amplified for 32 to 35 cycles at 95°C for 30 s, 62°C for 30 s, and 72°C for 30 s, followed by 7-min extension at 72°C. All primers were tested on Clontech Human Genomic DNA before using on cancer samples. For some samples, nested primers were also designed and used. All PCR products were purified using AmPure (Agencourt Bioscience Corp.) and sequenced on an Applied Biosystems 3730XL Genetic Analyzer using the BigDye terminator procedure.
All sequence data were edited using Sequencher software and analyzed with AutoSNP and Chromoscope software tools (GlaxoSmithKline internal software). Sequence variants were reconfirmed by independent PCR amplifications and sequencing.
To evaluate EGFR and HER2 gene sequences, quantitative PCR was run with probes for EGFR, HER2, and at least two housekeeping genes (HBB, SOD2, and, if enough sample was available, TLF7). Concurrently, standard curves were generated from commercially available genomic DNA (pooled blood from >100 healthy donors) and positive controls for HER2 and EGFR (cell lines with known gene amplification). Following normalization of the data using each housekeeping gene, the ratio of experimental to control sample was calculated for each patient. A ratio of ≥2 signified a gene copy increase. Of 62 samples tested, 5 did not have sufficient tumor cell content for analysis.
Statistical methods. The primary efficacy analysis was conducted on the targeted population. Demographic and disease characteristics were summarized using descriptive statistics. Response rates (percentage of patients achieving a complete or partial response), as determined by both the investigator and independent review panel, were summarized together with 95% confidence intervals, if warranted.
Qualitative and quantitative results were summarized for AEs and SAEs overall by age, relationship to lapatinib, and events leading to withdrawal. Qualitative assessments were summarized for clinical laboratory tests, vital signs, ECOG performance status, and echocardiogram/multigated acquisition scans. Qualitative and quantitative results were summarized for biomarkers obtained from tissue samples, and the relationship to tumor response was assessed.
The sponsor, through an independent data monitoring committee, reviewed the data from the first 30 targeted patients (∼15 patients per treatment group) once all 30 patients had been followed for a minimum of 16 wk. This review was intended to provide an opportunity to terminate the study early if there were concerns about safety or lack of efficacy in both treatment groups. The following rule was established about a decision to stop recruitment into the study for reasons of futility (lack of
Results
Patient characteristics. The study was conducted at 23 North American centers: 6 in Canada and 17 in the United States. The first patient was enrolled in November 2003 and the last patient was enrolled in February 2005. The data cutoff date used for this report was July 28, 2008. A total of 131 patients with advanced or metastatic NSCLC were randomized to treatment with lapatinib: 65 to 1,500 mg once daily and 66 to 500 mg twice daily. The demographic characteristics were similar between the treatment groups ( Table 1 ). The median age was 66 years (range, 32-86), the majority of patients were white (84%), and 56% of patients were women. Fifty-seven percent of patients were former smokers, 13% were current smokers, and 30% had never smoked. The majority of patients (59%) had adenocarcinoma without BAC features. One subject in each treatment group received prior systemic therapy. A total of nine subjects in each treatment group received prior radiotherapy. The proportion of patients withdrawing from the study and the reasons for withdrawal were similar between the treatment groups.
Response to therapy. At the interim analysis, conducted after 30 targeted patients had reached the initial response evaluation, the response rate determined by blinded independent review (complete or partial response) in the targeted population was 0% in both treatment groups. In the nontargeted population, one patient in the 1,500-mg once-daily group achieved a partial response (Table 2) . Stable disease or better by RECIST was seen in 31 of 131 (24%) patients.
Waterfall plots provide another graphic demonstration of efficacy of biological therapies that may produce mainly a cytostatic effect. The waterfall plot in Fig. 1 shows percentage change in maximum diameters of measurable disease from baseline to best response in all patients with postbaseline assessment by independent review. Despite the proportion of patients with stable disease, the study did not meet its predetermined interim end point goal for response and was stopped for futility. Patients who were on therapy without progression were given the option to continue lapatinib.
The Kaplan-Meier estimate of median progression-free survival in the targeted population was 15.6 weeks for the 1,500-mg once-daily group and 8.7 weeks for the 500-mg twice-daily group (Fig. 2A) . In the nontargeted population, the Kaplan-Meier estimate of median progression-free survival was 12.0 weeks for the 1,500-mg oncedaily group and 8.6 weeks for the 500-mg twice-daily group (Fig. 2B) . For all patients, median progression-free survival was 14.6 weeks for the 1,500-mg once-daily group and 8.7 weeks for the 500-mg twice-daily group (Fig. 2C) .
Overall survival in the targeted population was 60.9 weeks (15.2 months) for the 1,500-mg once-daily group and 55.4 weeks (13.9 months) for the 500-mg twice-daily group (Fig. 3A) . In the nontargeted population, overall survival was 45.4 weeks (11.4 months) for the 1,500-mg once-daily group and 32.4 weeks (8.1 months) for the Fig. 1 . Plot showing percent change from baseline for sum longest diameters (for measurable target lesions) at time of best overall response by independent review. Patients had one or more postbaseline assessment. Best overall response is progressive disease unless otherwise noted. Oncologist assessment was used when it differed from that of the radiologist for best overall response. If best overall response is stable disease (SD), lesion assessment is date associated with first stable disease. PR, partial response. 500-mg twice-daily group (Fig. 3B) . For all patients, overall survival was 58.0 weeks (14.5 months) for the 1,500-mg once-daily group and 45.1 weeks (11.3 months) for the 500-mg twice-daily group (Fig. 3C) .
Safety. All patients who received one or more dose of lapatinib (n = 131) were included in the evaluation of safety. The mean duration of exposure to study medication was 19.0 weeks in the 1,500-mg once-daily group and 14.5 weeks in the 500-mg twice-daily group. The mean daily dose in the 1,500-mg once-daily group was 1,447.9 mg and in the 500-mg twice-daily group was 966.7 mg.
The majority of patients in both treatment groups experienced one or more AE during the study (Table 3) . Diarrhea, rash, fatigue, nausea, and anorexia were the most common AEs in both treatment groups. Vomiting was more common in the 1,500-mg once-daily group (23%) than in the 500-mg twice-daily group (9%). Seven patients experienced an AE of pulmonary embolism: two patients in the 1,500-mg once-daily group (one being grade 3 and one grade 4) and five patients in the 500-mg twice-daily group [three with grade 4 pulmonary embolism and two with this AE of grade 5 (fatal)].
The incidence of AEs considered by the investigator to be related to study medication was similar in both treatment groups (89% for 1,500 mg once daily versus 83% for 500 mg twice daily). The most common treatment-related AEs in both treatment groups were diarrhea, rash, nausea, fatigue, and anorexia. These AEs occurred with similar frequency in both treatment groups. The incidence of AEs that led to permanent discontinuation Research.
on October 2, 2017. © 2010 American Association for Cancer clincancerres.aacrjournals.org Downloaded from was similar between treatment groups (11% for 1,500 mg once daily versus 15% for 500 mg twice daily), as were those that led to dose interruption (17% versus 18%, respectively). Diarrhea was the most common AE that led to permanent discontinuation in the 1,500-mg once-daily group (5% in this group), whereas nausea, vomiting, and pruritus were reported as the reason for permanent discontinuation with the most common frequency (2% each) in the 500-mg twice-daily group. An AE of diarrhea was also the most common reason for dose interruption (5% for 1,500 mg once daily versus 6% for 500 mg twice daily), followed by vomiting and nausea. Dose adjustment was required in 3% of patients receiving 1,500 mg once daily and in 6% of patients receiving 500 mg twice daily (Table 4 , included as Supplementary Data).
The incidence of SAEs overall was similar between the treatment groups. The most common SAEs were diarrhea (5%) in the 1,500-mg once-daily group and pulmonary embolism (8%) in the 500-mg twice-daily group. Five patients had fatal SAEs during the study: one patient in the 1,500-mg once-daily group (dyspnea) and four patients in the 500-mg twice-daily group (two patients died from pulmonary embolism, one from hypoxia, and one from pulmonary hemorrhage). None of the fatal events in this study was considered by the investigator to be related to the study medication.
The proportion of patients with SAEs considered by the investigator to be related to the study medication was similar between the treatment groups (8% in each). Diarrhea (5%) was the most common medication-related SAE in the 1,500-mg once-daily group. No single SAE considered related to treatment was observed in more than one patient in the 500-mg twice-daily group.
Decreased left ventricular cardiac ejection fraction has been reported with some patients taking lapatinib (23) . Three patients (5%) in the 1,500-mg once-daily group and none in the 500-mg twice-daily group experienced decreased ejection fraction during the study. Two of the three events (3%) seen in the 1,500-mg once-daily group were considered drug related and were classified as SAEs. Two of the three events were asymptomatic (grade ≤2), and one event was grade 3; none was fatal. One event resulted in permanent discontinuation of the study medication. No patients in either treatment group experienced interstitial pneumonitis.
Biomarker results. Archival tumor tissue was available for 92 patients (70%), and the relevant genes (EGFR, HER2, and KRAS) were sequenced successfully from 77 of these patients. Two patients (2.6%), both never smokers, had mutations only in EGFR (L858R and T790M; L858R). A third patient (a female former smoker) was found to harbor both EGFR (G719S and S768I) and KRAS (G12S) mutations. No mutations in HER2 were identified. None of the three patients with EGFR mutations responded to lapatinib. However, the mutations in two of the three patients may have conferred resistance to the medication, as both KRAS and T790M mutations are associated with resistance to EGFR tyrosine kinase inhibitors (24, 25) , including lapatinib (data not shown). The third patient with a mutation (L858R) had stable disease for 26 weeks.
Of the 77 patients with sufficient DNA for gene copy evaluation by quantitative PCR, 5 (8.8%) had increased EGFR copy number (range, 2-to 43-fold) and 2 (3.5%) had increased HER2 gene copy number (2-and 6-fold). Amplification of both genes in the same patient was not observed. These results could not be verified by fluorescent Table 3 . Summary of reported AEs with ≥10% total incidence regardless of relationship to study medication (safety population) Preferred term 1,500 mg once daily (n = 65) 500 mg twice daily (n = 66) (6) in situ hybridization due to insufficient remaining tissue. One patient with HER2 DNA amplification had a decrease of 51% in tumor measurement; however, this response was not confirmed.
Discussion
The primary objective of this study was to evaluate the overall response rate to lapatinib (complete or partial responses) in patients with advanced NSCLC. While the trial was being conducted, several studies of tyrosine kinase inhibitors in NSCLC reported that EGFR mutations were highly predictive of response (26) . Consequently, the study was amended to target patients with BAC features or those who had never smoked, as it was thought that these individuals were most likely to have EGFR mutations and, hence, would be more likely to respond to lapatinib therapy. However, only three patients (3.9% of those who could be tested) were found to have EGFR mutations. One possible reason for the low level of EGFR mutations, even within the targeted population, is that the majority of patients were white (84%) and, thus, less likely to harbor mutations in EGFR (27) . Alternatively, there could be technical limitations related to sample collection and to the sensitivity of the sequencing analysis. More sensitive techniques for detecting mutations were not evaluated in this study (19, 28) .
Lapatinib can inhibit the kinase activity of both EGFR and HER2. There is retrospective clinical evidence of EGFR inhibition in renal cell cancer, where in a phase III study of lapatinib versus hormonal therapy, relative prolongation of progression-free survival with lapatinib therapy was seen only in patients whose tumors expressed high levels (3+) of EGFR by immunohistochemistry (29) . Because no EGFR mutations have been described in renal cell cancer, this activity suggests that lapatinib is able to inhibit wildtype EGFR. Lapatinib also has activity against some EGFRmutant cell lines in vitro, although it seems less effective than gefitinib against the more commonly found mutations (30) . Clinically, lapatinib is active against HER2 + breast cancer (23) . The relative lack of clinical activity against tumors considered to be "EGFR driven" may be a function of either the different binding mechanism to EGFR (compared with erlotinib or gefitinib) or insufficient exposure at 1,500 mg once daily or 500 mg twice daily to inhibit EGFR in vivo. Neither explanation is entirely satisfactory, as both preclinical and clinical data support the mechanism of lapatinib activity being inhibition of EGFR phosphorylation (30) (31) (32) . However, recent structural analysis of EGFR bound to EGFR tyrosine kinase inhibitors suggests that lapatinib might not bind as effectively to mutated EGFR (due, for example, to steric hindrance by L858R; ref. 33) . Finally, although it is noteworthy that a patient with increased HER2 DNA levels seemed to benefit in this study, the rate of HER2 gene amplification in NSCLC is too low (estimated at ∼4% in unselected patients) to allow for a clinical study restricted to those patients (34) .
Two tyrosine kinase inhibitors, gefitinib and erlotinib, are approved for treatment of advanced NSCLC in patients previously treated with chemotherapy. Only erlotinib is presently available in the United States. As monotherapy in these patients, gefitinib improved tumor response rate (8.0% versus 1.3%; P < 0.0001) and time to treatment failure (hazard ratio, 0.82; 95% confidence interval, 0.73-0.92; P = 0.0006) versus placebo (35) and was recently shown to be noninferior to docetaxel (36) . Gefitinib has also shown activity in previously untreated (17% RECIST response rate, with 6% complete response) and treated (9% overall response, no complete response) patients, with overall survival at 3 years of 23% (95% confidence interval, 14-32%; ref. 16 ). Erlotinib monotherapy in pretreated patients with advanced NSCLC resulted in response rates of 8.9% versus <1% with placebo (P < 0.001), with a median duration of response of 7.9 and 3.7 months, respectively. Progression-free and overall survival also favored erlotinib (P < 0.001; ref. 37 ). Progression-free survival also was significantly prolonged by erlotinib maintenance therapy for patients with stable disease or better after first-line platinum-based chemotherapy in the preliminary report of the Sequential Tarceva in Unresectable NSCLC (SATURN) trial (38) . A small study of erlotinib monotherapy in selected patients resulted in an overall response rate of 22%, with an 83% response rate in patients with activating EGFR mutations (39) . Other tyrosine kinase inhibitors targeting two or more members of the ErbB gene family also have been tested in NSCLC, with promising results (40) (41) (42) (43) . Further studies of these agents are ongoing.
The major effect of tyrosine kinase inhibitors in NSCLC could be stabilization or slowed progression of disease without significant tumor shrinkage. Although objective responses by RECIST have been accepted as a valid measure of the antitumor activity of cytotoxic chemotherapy, they may not be the most appropriate measure of activity of cytostatic agents. Response rates may not capture the full benefit of treatment; delaying cancer progression is of direct benefit to the patient, as cancer progression is inevitably followed by morbidity and death. The rate of stable disease and the promising median survivals in this study seem to support this concept. Thus, time-to-event end points may be better overall predictors of efficacy than response rates (44) . The Kaplan-Meier estimate of median progression-free survival in the targeted population was 15.6 weeks for the 1,500-mg once-daily group and 8.7 weeks for the 500-mg twice-daily group. The 15.6-week estimated progression-free survival in the 1,500-mg oncedaily lapatinib group is in the 4-month range expected for first-line chemotherapy treatments in patients with good performance status and does suggest the possibility of some antiproliferative effect of the drug. In the nontargeted population, the median progression-free survival was 12.0 weeks for the 1,500-mg once-daily group and 8.6 weeks for the 500-mg twice-daily group. In the absence of an untreated control arm in this study, no conclusion can be reached with respect to the contribution of lapatinib to survival, and the study was not powered to compare survival between the two treatment arms.
Oral lapatinib (1,500 mg once daily and 500 mg twice daily) was well tolerated by patients with locally advanced/metastatic NSCLC. Diarrhea, rash, fatigue, nausea, and anorexia were the most common AEs in both treatment groups. The incidence of AEs and SAEs was generally similar between the treatment groups. Although no formal statistical comparison was done between the two treatment groups, it seems that both doses of lapatinib had similar safety profiles. Diarrhea and rash were observed in this study in 55% and 44% of patients, respectively, compared with 55% and 76% for erlotinib (37) and 27% and 37% for gefitinib (35) when used to treat NSCLC. Diarrhea is a known class effect of small-molecule EGFR tyrosine kinase inhibitors (45, 46) , and the rates and severity of diarrhea observed in this study are similar to those seen with lapatinib therapy of patients with breast cancer (23) . Rates of discontinuation due to toxicity were 13% for lapatinib (this study) and 5% for both erlotinib (37) and gefitinib (35) when used to treat NSCLC. It remains possible that higher doses of lapatinib could achieve clinical activity through EGFR inhibition, as the severity of skin rash seen with lapatinib seems to be mild compared with that seen with other EGFR inhibitors, and skin rash has been suggested as a predictor of response to erlotinib and gefitinib (47) .
Conclusions
This study was a randomized, open-label, multicenter, phase II study of lapatinib in patients with locally advanced or metastatic NSCLC. The doses tested failed to achieve a predetermined response rate in the targeted population at the interim analysis. Oral lapatinib at doses of 1,500 mg once daily and 500 mg twice daily was well tolerated in this population, and no overt differences in safety were noted between the two treatment regimens. Lapatinib as a single agent at the doses studied seems to have minimal single-agent activity, at least as measured by response rates, although progression-free survival in the 1,500-mg once-daily group was in the range that would be expected with first-line chemotherapy. The lower response rate compared with more selective EGFR inhibitors may be due to a different mechanism of activity against wild-type EGFR (48) or against mutant EGFR (30) . Alternatively, the dose levels that provide benefit for HER2-driven tumors (49) may be relatively less effective against EGFR. Although there may be a subgroup of patients who benefit, such as patients with HER2 amplification, this could not be determined by the current study. Further studies may be warranted to determine whether lapatinib is active in combination with other agents in the treatment of NSCLC.
